...
首页> 外文期刊>Journal of receptor and signal transduction research >An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal
【24h】

An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal

机译:用于人PD1 / PD-L1信号的体外产生和功能分析的优化方案

获取原文
获取原文并翻译 | 示例
           

摘要

Programmed cell death-1 (PD1) is an inhibitory receptor expressed on the activated T and B cells. Binding of PD1 to its ligands, PD-L1 and PD-L2 has led to deliver an inhibitory signal into the activated T cells. Recently, blocking PD1/PD-L1 pathway has emerged as a new treatment paradigm across a broad spectrum of malignancies. Remarkable clinical responses of monoclonal antibodies specific for PD-1 or its ligands in patients with many different types of cancer, attracted several pharmaceutical companies and researchers to investigate the agents that block PD1/PD-L1 signal. The safety and efficacy of the agents are needed to examine in the preclinical studies. In this study, we optimized a facile and cost-effective protocol for in vitro generation and functional analysis of human PD1/PD-L1 pathway. Activation of CD8+CD279+T cell was performed by anti-CD3 and D28 antibodies and the recombinant PD-L1 was used for inactivation of T cells through PD1/PD-L1 pathway. In this protocol, T-cell cytokine production (IL-2 and IFN-gamma) and proliferation assay confirmed that a measurable PD1/PD-L1 signal was generated. We expected that in vitro PD1/PD-L1 signal that has been optimized in this study will serve as a valuable protocol for preclinical studies involving PD1/PD-L1 pathway.
机译:编程的细胞死亡-1(PD1)是在活化的T和B细胞上表达的抑制受体。 PD1与其配体的结合,PD-L1和PD-L2的LED使抑制信号递送到活化的T细胞中。最近,阻断PD1 / PD-L1途径已成为广泛的恶性恶性肿瘤的新治疗范式。对于PD-1或其配体的单克隆抗体对许多不同类型癌症的患者的单克隆抗体的显着临床反应吸引了几家制药公司和研究人员,研究了阻断PD1 / PD-L1信号的药剂。需要在临床前研究中检查药剂的安全性和功效。在这项研究中,我们优化了对人PD1 / PD-L1途径的体外产生和功能分析的容易和经济效益的方案。通过抗CD3和D28抗体进行CD8 + CD279 + T细胞的活化,并使用重组PD-L1通过PD1 / PD-L1途径灭活T细胞。在该方案中,T细胞细胞因子产生(IL-2和IFN-Gamma)和增殖测定证实,产生了可测量的PD1 / PD-L1信号。我们期望在本研究中经过优化的体外PD1 / PD-L1信号将作为涉及PD1 / PD-L1通路的临床前研究的有价值的方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号